Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CYC 202

Known as: CYC-202, CYC202 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
AIM Phase I study of seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in clinical trials, the purine roscovitine… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
(R)-Roscovitine (CYC202) is often referred to as a “selective inhibitor of cyclin-dependent kinases.” Besides its use as a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Seliciclib (CYC202, R-roscovitine) is a cyclin-dependent kinase (CDK) inhibitor that competes for the ATP binding site on the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Deregulation of the cell cycle commonly occurs during tumorigenesis, resulting in unrestricted cell proliferation and… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
A new class of cell cycle inhibitors is currently entering clinical trials. These drugs exert their activity by inhibition of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
2003
Review
2003
Aberrations in cell cycle progression occur in the majority of human malignancies. The main pathway affected is the… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
CDK2 inhibitors have been proposed as effective anti‐cancer therapeutics. We show here that CYC202 (R‐roscovitine) is a potent… Expand
Is this relevant?